Supplemental Examination is a tool created by the America Invents Act ("AIA") that, according to the legislative history, was designed to give patent owners the ability to request that the USPTO review information that might later provide a basis for an inequitable conduct allegation if left unaddressed. Under 35 U.S.C. § 257, a patent owner may request Supplemental Examination of a patent to consider, reconsider, or correct information believed to be relevant to the patent.

The USPTO determines whether the information presented by the patent owner raises a substantial new question of patentability. If so, the USPTO orders ex parte reexamination.  

Those items of information considered by the USPTO during Supplemental Examination are, according to the statute, removed as a basis for a later finding of inequitable conduct. Such considerations may also be relevant to separate inquiries under the equitable doctrine of unclean hands.

Now that Supplemental Examination has been in place for a few years, we have an opportunity to evaluate how some patent owners have used it and what results the procedure has provided. In Part 1 of this article, we look at a Supplemental Examination request filed to address issues relating to 35 U.S.C. §112. In Part 2, we will discuss a Supplemental Examination request filed to address an inadvertent failure to cite prior art.

I. 35 U.S.C. 112: Confusion Raised Possible Indefiniteness, Lack of Written Description and Non-enablement Issues

In Supplemental Examination No. 96/000,267, patent owner Millennium Pharmaceuticals requested Supplemental Examination for U.S. Patent No. 8,859,504 (the '504 patent). The '504 patent includes 15 claims directed to compounds, crystalline forms, and a pharmaceutical composition.  

The patent owner requested Supplemental Examination only to review the patentability of crystalline form claims 6-14, in view of documents submitted by the applicant during prosecution and an expert declaration that was newly presented in the request for Supplemental Examination. The declaration discussed the relevance of the prosecution documents (a response to a restriction requirement and select pages of the as-filed application) to the issued crystalline form claims.

In this complex case, the expert declaration posited that the x-ray powder diffraction pattern peaks recited in crystalline form claims 6-14 did not correspond to the 5-membered ring compounds named in those claims, but rather to the 6-membered ring compounds taught in the examples in the application. Stated otherwise, in claims 6-14, each crystalline form recited a 5-membered ring, but, according to the declaration, what was disclosed in the specification and by the peaks recited in the claims was a 6-membered ring.  Millennium filed the Supplemental Examination request asserting that the data discrepancies "may render the claims unclear, raising a potential indefiniteness issue[]" and may also create a potential issue of written description support. (Supp. Exam Request).

The USPTO found that a substantial new question of patentability (SNQ) had been raised and ordered ex parte reexamination of claims 6-14 of the '504 patent. In particular, the Office noted that crystalline form claims 6-14 of the '504 patent were first presented as newly added claims during the original prosecution in the response to the restriction requirement and were entered without the applicant offering support in the specification.

Because the expert declaration explained that the peaks recited in claims 6-14 corresponded to a 6-membered ring crystalline form but not the 5-membered ring named in those claims, the Office concluded that "[t]here is a substantial likelihood that a reasonable examiner would consider these teachings [i.e., the expert declaration and the parts of the specification it relied on] important in deciding whether claims 6-14 were patentable." (Reasons for SNQ).

During the reexamination, the Office issued an Office Action, rejecting claims 6-14 as indefinite, non-enabled, and lacking written description. There was no action on the other patent claims because, at that point, supplemental examination had only been requested on claims 6-14, and the reexamination was only instituted on claims 6-14.

In response, the patent owner canceled claims 6-14 "[s]olely to expedite the reexamination of the patent[,]" and also amended claims 1, 3, and 15, even though those claims were not mentioned in the Request for Supplemental Examination and were not rejected. The patent owner corrected claim 3 to address an Office printing error. The patent owner amended claims 1 and 5 "for clarity or to correct typographical error(s)."

To view the full article please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.